Rationale and design of the Anti-Xa Therapy to Lower cardiovascular events in Addition to standard therapy in Subjects with Acute Coronary Syndrome–Thrombolysis in Myocardial Infarction 51 (ATLAS-ACS 2 TIMI 51) trial: A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of rivaroxaban in subjects with acute coronary syndrome

✍ Scribed by C. Michael Gibson; Jessica L. Mega; Paul Burton; Shinya Goto; Freek Verheugt; Christoph Bode; Alexei Plotnikov; Xiang Sun; Nancy Cook-Bruns; Eugene Braunwald

• Book ID: 116192431
• Publisher: Elsevier Science
• Year: 2011
• Tongue: English
• Weight: 428 KB
• Volume: 161
• Category: Article
• ISSN: 1097-6744
• DOI: 10.1016/j.ahj.2011.01.026